Filing Flows

Filing Flows › Companies › Sanara MedTech › Cash flow

Sanara MedTech cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$2.0M in Q2 2026 · $4.5M over twelve months

Operating cash flow$2.0M
Capital spending−$5K
Free cash flow+$2.0M

Analysis

In Q2 2026, Sanara MedTech generated $2.0M of operating cash flow and spent $5K on capital projects, leaving free cash flow of $2.0M. That is $1.1M more than in Q2 2025 ($903K).

Over the twelve months to Jun 30, 2026, operating cash flow was $5.7M; the largest uses were other investing ($4.7M), other financing ($1.3M), capital spending ($1.2M); the cash balance fell by $1.5M.

Operating cash flow was $2.0M against net income of −$453K. The largest differences: stock-based pay +$1.5M, receivables +$1.0M, depreciation & amortization +$619K.

Free cash flow

Sanara MedTech: free cash flow by quarterSanara MedTech: free cash flow by quarter$2.0MQ3 2024$860KQ4 2024−$3.7MQ1 2025$903KQ2 2025$1.1MQ3 2025$3.9MQ4 2025−$2.5MQ1 2026$2.0MQ2 2026
Operating cash flow less capital spending.
Sanara MedTech: operating cash flow against capital spendingSanara MedTech: operating cash flow against capital spendingOperating cash flowCapital spending$2.1M$9KQ3 2024$932K$72KQ4 2024−$2.0M$1.7MQ1 2025$2.7M$1.8MQ2 2025$2.2M$1.1MQ3 2025$3.9M$82KQ4 2025−$2.5M$44KQ1 2026$2.0M$5KQ2 2026
Latest (Q2 2026): Operating cash flow $2.0M, Capital spending $5K.

Capital allocation, year by year

Sanara MedTech: where the cash came from (up) and went (down), by fiscal yearSanara MedTech: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsFY2021: Operating cash flow −$4.8MFY2021: Shares issued $28.9MFY2021: Capital spending −$172K$28.9MFY2021FY2022: Operating cash flow −$5.6MFY2022: Asset sales $2KFY2022: Capital spending −$147KFY2022: Acquisitions −$2.5M$2KFY2022FY2023: Operating cash flow −$3.2MFY2023: Net borrowing $9.7MFY2023: Shares issued $911KFY2023: Asset sales $1KFY2023: Capital spending −$265KFY2023: Acquisitions −$9.9M$10.6MFY2023FY2024: Operating cash flow −$24KFY2024: Net borrowing $19.6MFY2024: Shares issued −$75KFY2024: Capital spending −$206K$19.6MFY2024FY2025: Operating cash flow $6.8MFY2025: Net borrowing $12.0MFY2025: Asset sales $60KFY2025: Capital spending −$4.6M$18.9MFY2025
Over these 5 years operating cash flow totalled −$6.9M; the largest uses were operating cash flow ($13.6M) and acquisitions ($12.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$15.4M
Debt$46.5M
Net debt$31.1M

Sanara MedTech funds itself: free cash flow was $4.5M over the last twelve months, and $15.4M of cash and investments stands against $46.5M of debt.

Where the cash came from and went

Sanara MedTech: sources (+) and uses (−) of cash, Q2 2026Sanara MedTech: sources (+) and uses (−) of cash, Q2 2026Operating cash flow$2.0MCash drawn (+) / kept (−)−$1.8MOther financing−$206KCapital spending−$5K
Sanara MedTech: sources (+) and uses (−) of cash, TTM to Q2 2026Sanara MedTech: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow$5.7MOther investing−$4.7MCash drawn (+) / kept (−)$1.5MOther financing−$1.3MCapital spending−$1.2M

From profit to cash

Sanara MedTech: net income to operating cash flow, Q2 2026Sanara MedTech: net income to operating cash flow, Q2 2026Net income−$453KDepreciation & amortization$619KStock-based pay$1.5MGains on disposals$1KReceivables$1.0MInventory−$407KPayables$496KPrepaid and other assets$88KOperating cash flow$2.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q2 2026$2.0M−$5K—−$1.8M$2.0M
Q1 2026−$2.5M−$44K—$3.0M−$2.5M
Q4 2025$3.9M−$82K—−$1.6M$3.9M
Q3 2025$2.2M−$1.1M—$2.0M$1.1M
Q2 2025$2.7M−$1.8M−$44K$3.7M$903K
Q1 2025−$2.0M−$1.7M$12.1M−$4.8M−$3.7M
Q4 2024$932K−$72K—$399K$860K
Q3 2024$2.1M−$9K$15.2M−$10.1M$2.0M

Sanara MedTech: income statement and cash flow

Sanara MedTech, Q2 2026: revenue $28.1M (+9% year over year), operating margin 6.3%. The chart follows the revenue to costs, profit and cash.

Sanara MedTech: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.